Hollings Cancer Center, US, has enrolled the first subject in the Phase II/III FORTIFI-NH01 trial of ficerafusp alfa to treat ...

The first Korean company granted Breakthrough Therapy Designation (BTD) from the U.S. FDA-Clinical trials and results from a three-year follow-up show significant improvements compared to existing ...

Merck's stock recently got a cardio boost, jumping 13% in a month thanks to some pulse-quickening developments. The company ...

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo.

Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff ...

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...

Merck & Co’s attempts to move its checkpoint inhibitor Keytruda into prostate cancer have been blocked once again, continuing a run of disappointing studies with immunotherapies in the disease.

Pfizer’s CEO Albert Bourla has revamped sales tactics, leading to a 31% rise in U.S. sales of Nurtec migraine medication, reports The Wall Street Journal.

The sportswear company will increase marketing investments by 40% in support of “Go Wild,” a campaign that reworks Afroman’s “Because I Got High.” ...

Soon-to-be medical school graduates received 877 more primary care position offers in the 2025 Main Residency Match compared with the previous year, according to the National Resident Matching ...